BRIEF published on 04/07/2026 at 07:35, 2 months 20 days ago Evotec Proposes Dieter Weinand as New Supervisory Board Chairman Strategic Partnerships Supervisory Board Evotec Pharmaceutical Leadership Dieter Weinand
PRESS RELEASE published on 04/07/2026 at 07:30, 2 months 20 days ago Evotec Nominates Dieter Weinand as Supervisory Board Chairman Evotec SE nominates Dieter Weinand as Supervisory Board Chairman, aiming to enhance commercial execution, strategic partnerships, and profitability Strategic Partnerships Supervisory Board Chairman Evotec SE Commercial Execution Dieter Weinand
BRIEF published on 04/01/2026 at 11:15, 2 months 26 days ago Evotec SE to Release 2025 Financial Results Financial Results Drug Discovery Evotec SE Webcast 2025 Performance
BRIEF published on 04/01/2026 at 11:15, 2 months 26 days ago Evotec SE publiera ses résultats financiers de 2025 Résultats Financiers Evotec SE Webdiffusion Découverte De Médicaments Performances 2025
PRESS RELEASE published on 04/01/2026 at 11:10, 2 months 26 days ago Evotec SE to Announce Fourth Quarter and Full-Year 2025 Results on April 8, 2026 Evotec SE will announce its Q4 and full-year 2025 financial results on April 8, 2026, through a webcast and conference call held in English. Learn more at www.evotec.com Financial Results Conference Call Drug Discovery Evotec SE Webcast
BRIEF published on 04/01/2026 at 07:35, 2 months 26 days ago Evotec Appoints Dr. Ashiq H. Khan as Chief Commercial Officer AI Innovation Biotech Leadership Evotec Commercial Strategy
BRIEF published on 04/01/2026 at 07:35, 2 months 26 days ago Evotec nomme le Dr Ashiq H. Khan au poste de directeur commercial Biotechnologie Direction Stratégie Commerciale Evotec Innovation En IA
PRESS RELEASE published on 04/01/2026 at 07:30, 2 months 26 days ago Evotec Appoints Dr. Ashiq H. Khan as Chief Commercial Officer Evotec SE appoints Dr. Ashiq H. Khan as Chief Commercial Officer, bringing over 15 years of international leadership experience in biotech, CRO, and AI-driven platforms Chief Commercial Officer Evotec SE Biotech AI-driven Platforms Dr. Ashiq H. Khan
BRIEF published on 03/23/2026 at 07:35, 3 months 4 days ago Evotec Biologics s'associe à BARDA pour améliorer la production d'anticorps contre Ebola Evotec BARDA Bioproduction Ebola Anticorps
BRIEF published on 03/23/2026 at 07:35, 3 months 4 days ago Evotec Biologics Partners with BARDA to Enhance Antibody Production Against Ebola Evotec BARDA Biomanufacturing Ebola Antibodies
Published on 06/27/2026 at 01:40, 10 hours 50 minutes ago Polaris Renewable Energy Announces Results of Director Elections at Annual and Special Meeting
Published on 06/27/2026 at 00:00, 12 hours 30 minutes ago Onco-Innovations Initiates Three-Species Hepatocyte and Microsome Metabolism Studies for ONC010
Published on 06/26/2026 at 23:00, 13 hours 30 minutes ago Canadian North Resources Inc. Announces Results of 2026 Annual General and Special Shareholders Meeting
Published on 06/26/2026 at 22:50, 13 hours 40 minutes ago Banyan Gold Files Technical Report for AurMac Project, Yukon, Canada
Published on 06/26/2026 at 22:15, 14 hours 15 minutes ago Revive Therapeutics Announces Proposed Private Placement
Published on 06/27/2026 at 00:05, 12 hours 25 minutes ago EAN Congress: Hearing aid use linked to 23% lower dementia risk in people with both epilepsy and hearing loss
Published on 06/27/2026 at 00:04, 12 hours 26 minutes ago Persistent and Nagarro sign Business Combination Agreement to form the Persistent - Nagarro Group, a global leader in AI-led digital engineering
Published on 06/26/2026 at 23:36, 12 hours 54 minutes ago Persistent and Nagarro sign Business Combination Agreement to form the Persistent – Nagarro Group, a global leader in AI-led digital engineering
Published on 06/26/2026 at 23:36, 12 hours 54 minutes ago EQS-Adhoc: Nagarro SE: Nagarro signs business combination agreement with Persistent Systems and supports voluntary public takeover offer to all shareholders at EUR 81 per share
Published on 06/26/2026 at 23:27, 13 hours 3 minutes ago EQS-WpÜG: Takeover Offer / Target company: Nagarro SE; Bidder: Galaxy Germany Holding SE
Published on 06/26/2026 at 17:45, 18 hours 45 minutes ago Descriptif du programme de rachat d'actions
